ckd

Topoisomerase I inhibitor. Forms stable DNA-topoisomerase complexes during DNA replication and induces cell cycle arrest in the G2/M phase. Inhibits growth of a range of cancer cell lines in vitro, as well as of ovarian and leukemia tumors in vivo.

CKD-712 is a nuclear factor NF-kappa B inhibitor. CKD-712 suppressed MMP-9, but not MMP-2 and other NF-κB-regulated proteins involved in cancer metastasis such as VEGF. CKD-712 induced cell cycle arrest at G2M phase by suppressing cyclin A, cyclin B and C

CKD-519 is a selective inhibitor of cholesteryl ester transfer protein (CETP). It inhibits CETP-mediated transfer of cholesteryl ester in human serum (IC50: 2.3 nM).

Valecobulin hydrochloride (CKD-516 hydrochloride) is a potent inhibitor of β-tubulin polymerization. Valecobulin hydrochloride is a valine prodrug and a vascular disrupting agent.

Lobeglitazone Sulfate（CKD-501 Sulfate） is a novel thiazolidinedione with anti-inflammatory activity that inhibits LPS-induced NLRP3 inflammasome activation and hepatic inflammation, and can be used in the study of type 2 diabetes mellitus (T2DM).

Beloranib is a fumagillin anticancer drug. Beloranib belongs to an angiogenesis inhibitor.

Tenofovir disoproxil aspartate, a nucleotide reverse transcriptase inhibitor, is used potentially for the treatment of HBV infection.

Belotecan hydrochloride (CKD-602) is a synthetic water-soluble camptothecin derivative and topoisomerase I inhibitor with potential antitumor activity

Valecobulin is a potent β-tubulin polymerization inhibitor. Valecobulin is a valine prodrug of (S516) and an avascular disrupting compound.

Bis-T-23 is a promoter of actin-dependent dynamin oligomerization, an HIV-I integrase inhibitor, and a Telstar derivative. Bis-T-23 promotes actin-dependent dynamin oligomerization. Bis-T-23 can be used in studies of HIV and chronic kidney disease (CKD).

Lockdown is a reversible and non-competitive PPM1F inhibitor. Lockdown is selective for PPM1F, because this compound does not inhibit other protein phosphatases in vitro and does not induce additional phenotypes in PPM1F knockout cells. Lockdown acts in a dose-dependent, allosteric manner with high selectivity for PPM1F

Ziltivekimab (COR-001), a human anti-IL-6 monoclonal antibody, efficiently lowers serum CRP levels and exhibits anti-inflammatory properties. It is potentially useful in researching chronic systemic inflammation and cardiovascular diseases linked to chronic kidney disease (CKD) [1].

NS-3-008 hydrochloride (NS-3-008 HCl) is a transcriptional G0/G1 switch 2 (G0s2) inhibitor( IC50 of 2.25 μM).

Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).

CDDO-dhTFEA, a synthetic oleanane triterpenoid, effectively activates Nrf2 while inhibiting the NF-κB pro-inflammatory transcription factor. It restores mean arterial pressure (MAP), elevates Nrf2 levels and the expression of related genes, attenuates NF-κB and transforming growth factor-β pathway activation, and mitigates glomerulosclerosis, interstitial fibrosis, and inflammation in rats with chronic kidney disease (CKD).

Belotecan (CKD-602 free base) is an inhibitor of DNA topoisomerase I. Belotecan blocks the cell cycle and induces apoptosis and is an antitumour derivative of camptothecin that can be used in cancer research.

R-268712 is a specific activin receptor-like kinase 5 (ALK5) inhibitor(IC50 of 2.5 nM). It is also an orally active transforming growth factor-β type I receptor inhibitor.

p-Cresyl Sulfate is a major uremic toxin found in the blood of patients with chronic kidney disease (CKD), derived from the metabolites of tyrosine and phenylalanine in the liver.

Sodium zirconium cyclosilicate, an orally administered, non-absorbed, microporous zirconium silicate, acts as a highly selective cation exchanger to remove excess potassium (K+) in vivo. It has potential use in the research of chronic kidney disease (CKD) [1] [2].

TRPC5-IN-4, a potent and safe TRPC inhibitor, exhibits IC50 values of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively, indicating high efficacy. It does not cause damage to liver and kidney cellular components, making it suitable for chronic kidney disease (CKD) research [1].

UK-396082 is a potent inhibitor of thrombin-activated fibrinolytic inhibitor (TAFI), enhancing plasmin activity while concurrently reducing levels of the extracellular matrix (ECM). This compound is valuable for research on chronic kidney disease (CKD).

BI-685509 is a potent and orally active sGC activator. BI-685509 restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. BI-685509 can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .

Poricoic acid A (Poricoic acid A(F)) is a natural product with antitumor activity. It also enhances melatonin inhibition of AKI-to-CKD transition by regulating the Gas6/AxlNFκB/Nrf2 axis.

S516 is an active CKD-516 metabolite and is a potent inhibitor of tubulin polymerization(IC50 of 4.29 μM), has marked antitumor activity.

Lobeglitazone, also known as CKD-501, is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.